{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-040523","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.844417+00:00","generated_at":"2026-05-30T17:07:38.587629+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oragenics updates on concussion drug ONP-002 progress; Phase II trial preparation advanced","bullets":["ONP-002 cleared FDA cardiotoxicity and genotoxicity tests; spray-dry formulation completed with 4-fold drug increase per dose.","$4.45M public offering closed Sep 2024; total $6M+ raised in 2024 to fund Phase II trial.","Phase II trial planned later 2024, first in Australia then U.S.; evaluates efficacy on symptom reduction and functional recovery.","Appointed Dr. James Kelly as CMO and Dr. William Peacock as CCO in 2024 for clinical oversight.","Partnership with Avance Clinical in May 2024; Australian Regulatory Submission Brochure targeted Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-040523","json":"https://secwatch.observer/filing/0001493152-24-040523.json","markdown":"https://secwatch.observer/filing/0001493152-24-040523.md","text":"https://secwatch.observer/filing/0001493152-24-040523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224040523/0001493152-24-040523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224040523/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:07:38.587629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}